BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Director Mark A. Sirgo sold 100,000 shares of BioDelivery Sciences International stock in a transaction that occurred on Tuesday, April 10th. The stock was sold at an average price of $2.06, for a total transaction of $206,000.00. Following the completion of the sale, the director now directly owns 2,585,966 shares in the company, valued at approximately $5,327,089.96. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Shares of BDSI opened at $2.25 on Friday. The stock has a market capitalization of $131.51, a price-to-earnings ratio of -5.77 and a beta of 0.44. The company has a debt-to-equity ratio of 5.37, a quick ratio of 1.29 and a current ratio of 1.52. BioDelivery Sciences International, Inc. has a fifty-two week low of $1.60 and a fifty-two week high of $3.60.
BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings data on Thursday, March 15th. The specialty pharmaceutical company reported ($0.29) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.05). BioDelivery Sciences International had a return on equity of 22.93% and a net margin of 8.52%. The business had revenue of $12.51 million during the quarter, compared to analysts’ expectations of $9.83 million. equities analysts predict that BioDelivery Sciences International, Inc. will post -0.77 earnings per share for the current year.
Several analysts have weighed in on the stock. Seaport Global Securities began coverage on shares of BioDelivery Sciences International in a research note on Friday, January 26th. They set a “buy” rating and a $5.00 price objective for the company. Zacks Investment Research raised shares of BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research note on Wednesday, February 14th. ValuEngine downgraded shares of BioDelivery Sciences International from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. Cantor Fitzgerald reiterated a “buy” rating and set a $5.00 price target on shares of BioDelivery Sciences International in a research report on Thursday, March 15th. Finally, HC Wainwright set a $4.00 price target on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research report on Monday, March 19th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $4.25.
BioDelivery Sciences International Company Profile
BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.